Truist Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Truist Financial’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,000	Closed	-$56K	–	2720
2021 Q2	$56K	Hold	21,000	–	–	﹤0.01%	2670
2021 Q1	$65K	Hold	21,000	–	–	﹤0.01%	2587
2020 Q4	$75K	Buy	+21,000	New	+$84.6K	﹤0.01%	2487

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Truist Financial's CRVS Position: Q3 2021 in Review

Truist Financial sold out of Corvus Pharmaceuticals (CRVS) in Q3 2021, closing a stake of 21,000 shares — an estimated $56K sold.

Truist Financial first reported a position in CRVS in Q4 2020 and held it in 3 quarters. The position peaked at $75K in Q4 2020. 61 funds tracked by Wall St. Rank hold CRVS as of Q3 2021.

Truist Financial reported no remaining Corvus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Truist Financial sold 21,000 Corvus Pharmaceuticals shares in Q3 2021, an estimated $56K.
Truist Financial first reported a position in Corvus Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Truist Financial's Corvus Pharmaceuticals position peaked at $75K in Q4 2020.
61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2021.

Based on Truist Financial's 13F filing for Q3 2021, filed 5 Nov 2021.